Table 1:
Baseline Demographics and Participant Characteristics
| Exercise Group | Sleep Hygiene Group | p-value | |
|---|---|---|---|
| N | 27 | 28 | -- |
| Randomization Strata: N | |||
| Males age 45-65 | 9 | 9 | |
| Females age 45-65 | 5 | 4 | X=0.72 |
| Males age >65 | 7 | 10 | p=0.87 |
| Females age >65 | 6 | 5 | |
| Age | |||
| Mean ± SD | 65.33 ± 8.17 | 65.82 ± 5.19 | t=0.26 |
| Range | 45-78 | 54-77 | p=0.79 |
| Sex N (%) | |||
| Male | 16 (59.3) | 19 (67.9) | X=0.44 |
| Female | 11 (40.7) | 9 (32.1) | p=0.51 |
| DOD (years) | z=−1.57 | ||
| Median (IQR) | 6.0 (3.0-9.0) | 3.0 (1.0-7.5) | p=0.12 |
| MDS-UPDRS part I | z=−0.96 | ||
| Median (IQR) | 7.0 (5.0-11.0) | 9 (6.0-12.5) | p=0.34 |
| MDS-UPDRS part II | t=−1.31 | ||
| Mean ± SD | 11.11 ± 5.88 | 9.14 ± 5.28 | p=0.20 |
| MDS-UPDRS part III | t=−1.45 | ||
| Mean ± SD | 33.48 ± 12.39 | 28.11 ± 15.02 | p=0.15 |
| MDS-UPDRS part IV | z=0.14 | ||
| Median (IQR) | 3.0 (0.75-5.0) | 3.0 (0.0-6.0) | p=0.88 |
| MDS-UPDRS Total | t=−1.20 | ||
| Mean ± SD | 56.46 ± 18.13 | 50.07 ± 20.91 | p=0.23 |
| LED | z=−1.08 | ||
| Median (IQR) | 640.0 (440.0-855.0) | 482.5 (300.0-748.8) | p=0.28 |
Normality tested with Shapiro-Wilks and non-parametric test reported (Wilcoxon z) if not normal. DOD: Duration of disease; LED: Levodopa Equivalent Dose; MDS-UPDRS: Movement Disorders Society-Unified Parkinson’s Disease Rating Scale.